PIRS News and Press, Pieris Pharmaceuticals Inc. From 08/27/21

In 2019, tiny Axsome Therapeutics (NASDAQ: AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech, Novavax (NASDAQ: NVAX) , came out of nowhere to stomp the stock mark...

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announ...

Pieris Pharmaceuticals (NASDAQ:PIRS): Q2 GAAP EPS of -$0.25 beats by $0.02. Revenue of $3.29M (-70.8% Y/Y) beats by $1.21M. Cash and cash equivalents totaled $119.1M for the quarter ended June 30, 2021, compared to a cash and cash equivalents balance of $70.4M for the year ended December 31, ...

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibro...

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer Shane Olwill, Ph.D., promoted to Chief Development Officer BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biothera...

BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today annou...

Jefferies has reiterated its buy rating on shares of Pieris Pharmaceuticals ([[PIRS]] +3.5%) and has raised its price target from $6 to $8.Analyst Roger Song writes that the announcement on June 25 that the company secured a a €14.2M (~$17M) grant for the development of PRS-220 fo...

Fuwei Films (FFHL) +56% on Q1 results.Osmotica Pharmaceuticals (OSMT) +44% on deal to sell business and manufacturing facility.Pieris Pharmaceuticals (PIRS) +21% on development plans for PRS-220 in lung disease.Property Solutions Acquisition (PSAC) +16% on b...

Pieris Pharmaceuticals (PIRS) jumps 17% premarket after announcing the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor, also known as CCN2, for the treatment of idiopathic pulmonary fibrosis ((IPF)).in addition, the Company has bee...

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary f...